Neuland Laboratories Limited

NSE NEULANDLAB.NS

Neuland Laboratories Limited Gross Profit Margin for the year ending March 31, 2024: 52.92%

Neuland Laboratories Limited Gross Profit Margin is 52.92% for the year ending March 31, 2024, a 9.17% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Neuland Laboratories Limited Gross Profit Margin for the year ending March 31, 2023 was 48.47%, a 20.64% change year over year.
  • Neuland Laboratories Limited Gross Profit Margin for the year ending March 31, 2022 was 40.18%, a 1.59% change year over year.
  • Neuland Laboratories Limited Gross Profit Margin for the year ending March 31, 2021 was 39.55%, a 7.06% change year over year.
  • Neuland Laboratories Limited Gross Profit Margin for the year ending March 31, 2020 was 36.95%, a 17.67% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
NSE: NEULANDLAB.NS

Neuland Laboratories Limited

CEO Mr. Davuluri Sucheth Rao
IPO Date Oct. 13, 2008
Location India
Headquarters Phoenix IVY Building
Employees 1,643
Sector Health Care
Industries
Pharmaceuticals
Description

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.

StockViz Staff

January 15, 2025

Any question? Send us an email